Papers/PMID:41125682
Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.
Scientific reports2025The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
melatonin — decreases malondialdehyde (circulating)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The reduction in serum MDA in the melatonin group was also statistically significant when compared to the placebo group ( P = 0.03; Table 3).”
Quoted verbatim from Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.. - Study
- RCT
- Dose
- Melatonin 5 mg tablet, one tablet nightly one hour before bedtime, for 10 weeks
- Population
- Adults aged 19-75 with chronic kidney failure on continuous ambulatory peritoneal dialysis, four PD centres in Iran; 46 recruited, 44 analysed (22 melatonin, 22 placebo) after one exclusion per group for peritonitis; serum MDA was a pre-specified PRIMARY outcome; double-blind, placebo-controlled; MDA measured in serum by colorimetric commercial kit (ZellBio GmbH), intra-assay CV 5.5%; between-group comparison of change from baseline at week 10
Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.2025PMID:41125682Industry fundedPermalink
melatonin — decreases C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“During the study, serum hs-CRP levels decreased in the melatonin group, and this reduction was significant in comparison with the placebo group ( P = 0.04).”
Quoted verbatim from Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.. - Study
- RCT
- Dose
- Melatonin 5 mg tablet, one tablet nightly one hour before bedtime, for 10 weeks
- Population
- Adults aged 19-75 with chronic kidney failure on continuous ambulatory peritoneal dialysis, four PD centres in Iran; 46 recruited, 44 analysed (22 melatonin, 22 placebo) after one exclusion per group for peritonitis; serum hs-CRP was a pre-specified PRIMARY outcome and the variable the trial was powered on; double-blind, placebo-controlled; hs-CRP by ELISA (ZellBio GmbH), intra-assay CV 5.1%; between-group comparison of change from baseline at week 10
Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.2025PMID:41125682Industry fundedPermalink